Is Pluri, Inc. overvalued or undervalued?

As of 13 May 2025, the valuation grade for Pluri, Inc. has moved from does not qualify to risky, indicating a deteriorating outlook. The company is overvalued, as reflected by its negative Price to Book Value of -8.32 and an EV to EBITDA ratio of -1.69, both of which suggest significant financial distress. Additionally, the EV to Sales ratio stands at 34.89, indicating that the market is pricing the company at an extremely high multiple relative to its sales.
In comparison to its peers, Pluri, Inc. has a less favorable EV to EBITDA ratio than Equillium, Inc. at -4.9420 and OncoCyte Corp. at -2.1276, highlighting its relative weakness within the industry. Furthermore, the company's recent stock performance has been poor, with a 1-year return of -13.35% compared to the S&P 500's 17.14%, reinforcing the notion that Pluri, Inc. is struggling significantly in the market.